AMK

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of AMK

What is AMK? (Amoxicillin/Clavulanic Acid)

Property Description
Active Ingredients Amoxicillin and Clavulanic acid
Form Oral tablet (various releases) or powder for oral suspension
Pharmacological Class beta-Lactam Antibiotic and beta-Lactamase Inhibitor Combination
Common Use Treating a wide range of bacterial infections
Origin Semisynthetic

What Type of Medicine is Amoxicillin/Clavulanic Acid?

Amoxicillin/Clavulanic Acid, often referred to as Co-amoxiclav, is clinically recognized as a fixed-dose combination antibiotic and is a broad-spectrum antibacterial drug used to fight infections caused by susceptible bacteria. This medicine belongs to the beta-lactam class of antibacterials. This combination unites the semisynthetic penicillin derivative Amoxicillin with the ancillary agent Clavulanic acid, which functions as a beta-lactamase inhibitor. This medicinal entity is included in the World Health Organization (WHO) Model List of Essential Medicines, signifying its critical global importance as an accessible treatment.

The Composition: Amoxicillin and Clavulanic Acid Explained

The product's identity rests on its two active ingredients: the primary cell wall-disrupting agent, Amoxicillin (typically as Amoxicillin trihydrate), and the resistance-neutralizing agent, Clavulanic acid (usually formulated as Clavulanate potassium salt). Clavulanic acid itself is a naturally derived beta-lactam produced through fermentation. This combination is specifically designed for oral administration, and its formulation in a powder for oral suspension is often used for pediatric patients. The drug is manufactured in several high-level dosage forms, including immediate-release tablets, extended-release tablets, and the aforementioned oral suspension.

What is the Unique General Purpose of This Combination?

The general purpose of combining these two components is to overcome bacterial defense mechanisms and effectively broaden the antibacterial activity. Many bacterial strains have evolved to produce beta-lactamase enzymes that destroy Amoxicillin before it can exert its full bactericidal effect. By inactivating these enzymes, Clavulanic acid protects the Amoxicillin, allowing it to target and kill bacteria that would otherwise be resistant to the penicillin derivative alone. This pairing reliably extends the utility of the antibiotic in scenarios where bacterial drug resistance is a known concern.

Regulatory References

  1. Amoxicillin + clavulanic acid - eEML - Electronic Essential Medicines List
  2. WHO Model List of Essential Medicines (EML) homepage

What side effects are possible with AMK?

Possible Side Effects and Safety Information

The safety profile for Amoxicillin/Clavulanic Acid (AMK) is organized by regulatory authorities based on the affected organ system and the reported frequency of the event. The most commonly reported events are generally related to the gastrointestinal system.

Frequency-Classified Adverse Reactions

Side effects that are classified as Very Common in official regulatory documents include diarrhea. Reactions listed as Common include nausea, vomiting, and mucocutaneous candidosis (thrush). Less frequent events, classified as Uncommon, include headache, dizziness, indigestion, skin rash, and temporary increases in liver enzymes (AST/ALT).

Serious Adverse Reactions and Safety Constraints

Official labeling documents identify several serious adverse reactions, notably severe beta-lactam hypersensitivity reactions such as anaphylaxis and angioedema, requiring immediate avoidance in patients with a history of beta-lactam allergy. Additionally, severe cutaneous reactions (SCAR), including Stevens-Johnson Syndrome (SJS), and serious hepatobiliary events such as hepatitis and cholestatic jaundice, are documented.

These hepatic events, while rare, may be delayed, sometimes appearing weeks after treatment has concluded. The medicine is formally contraindicated in patients with a history of liver dysfunction associated with a prior use of this combination or a known allergy to penicillins. Population-specific safety notes also exist, including caution for use in patients with renal or hepatic impairment and the need to avoid the drug if infectious mononucleosis is suspected due to the increased risk of rash.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Amoxicillin/Clavulanic Acid (AMK) strictly defines overdosage by specific clinical manifestations and mandated emergency actions. Overdosage may result in symptoms related to the gastrointestinal and renal/urinary systems, including diarrhea, stomach pain, and sleepiness.

Documented Severe Manifestations

More severe effects involve the Central Nervous System, where convulsions or seizures may occur, particularly in patients with pre-existing impaired renal function. The official profile also notes the risk of crystalluria, which can lead to signs such as bloody or cloudy urine and greatly decreased frequency of urination.

Mandated Emergency Actions

The guidance mandates seeking immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if severe, life-threatening signs are observed, such as collapse, seizure activity, trouble breathing, or inability to be awakened. In all other cases of suspected overdosage, the patient should contact a poison control helpline or an emergency medical provider.

Official Management Procedures

Management of AMK overdosage is strictly symptomatic and supportive, as a specific antidote is not known. The primary procedural measure documented for eliminating the drug is hemodialysis, which effectively removes both amoxicillin and clavulanate from circulation. Maintaining adequate fluid intake and monitoring urinary output are officially advised supportive steps to mitigate the risk of crystalluria.

Therapeutic Uses of AMK

What AMK Treats: Main Uses and Benefits

The combination of amoxicillin and clavulanic acid (AMK) is a broad-spectrum medicine generally used when bacterial resistance is considered relevant, providing support that helps ease the overall symptom burden in a variety of acute conditions.

Addressing Difficult Respiratory and Ear Infections

This medication is commonly used to help with acute bacterial infections of the lower respiratory tract, such as community-acquired pneumonia, and infections in the ear, nose, and throat (ENT) domain, including severe sinusitis and acute otitis media. It helps address symptom clusters that may become intense or disruptive, such as fever, persistent nasal discharge, and localized pain, especially in situations where patients experience symptoms related to inflammatory or irritative states.

This combination is commonly used to help with conditions affecting the ears, lungs, sinus, skin, and urinary tract. This therapeutic approach is relevant for addressing the bacterial cause of symptoms, which may support the resolution of acute manifestations. This contributes to easing the overall symptom load and supports patients during difficult episodes by easing distress.

Treating Resistant Skin, Tissue, and Systemic Issues

AMK is applied in contexts where additional symptomatic support is needed for skin and soft tissue infections, like cellulitis, and specific systemic issues such as complicated urinary tract infections. It may assist with managing symptoms that create noticeable physiological strain, such as widespread swelling, pain, and fever. The medication supports the patient during difficult episodes by easing discomfort and assists with maintaining functional stability, especially when symptoms related to physical discomfort intensify temporarily.

Quick Fact: Supports Easing Localized Pain and Swelling

The information is based on general therapeutic domains.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use AMK?

Eligibility to use Amoxicillin/Clavulanic Acid (AMK) is strictly defined by regulatory authorities based on patient history, age, and physiological status.

Contraindications (Must Not Use):

  • Patients with a known history of serious hypersensitivity reactions (e.g., anaphylaxis) to AMK or any other penicillin/beta-lactam antibiotic (e.g., cephalosporins).
  • Patients with a history of cholestatic jaundice or hepatic dysfunction previously associated with AMK use.

Conditional Use and Restrictions:

  • Renal Impairment: Patients with severe kidney impairment (Creatinine Clearance <30 mL/min) are ineligible for specific high-dose tablet formulations. Other eligible formulations require a medically managed dosing schedule.
  • Hepatic Impairment: Use requires caution and regular monitoring of liver function.
  • Mononucleosis: AMK use should generally be avoided in patients with infectious mononucleosis due to the high risk of a generalized rash.
  • Pregnancy and Lactation: Use is conditional and requires caution; it is generally reserved for when the need is clearly established by a healthcare professional.

Age and Weight:

  • Use is established for adults and older adults (though dose adjustment may be necessary if age-related kidney decline is present).
  • Children weighing less than 40 kg are not recommended to use most tablet formulations, as they require specific liquid or pediatric formulations to ensure the correct drug ratio.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Amoxicillin/Clavulanic Acid (AMK) as stated in government regulatory labeling.

Element Description (Regulatory Basis)
Interacting Medicinal Products Agents affecting renal tubular secretion (Probenecid, Methotrexate), Oral Anticoagulants, Mycophenolate Mofetil (MMF), Allopurinol, and Oral Contraceptives.
Pharmacokinetic Basis Inhibition of renal tubular secretion, resulting in altered systemic exposure to the co-administered drug or to Amoxicillin. Pharmacodynamic effect on coagulation parameters.
Interaction Restriction Co-administration with Probenecid is formally restricted in labeling due to its effect of increasing and prolonging amoxicillin plasma concentrations.
Administration Constraint Administration must occur at the start of a meal to enhance the absorption of the clavulanate component and minimize potential gastrointestinal intolerance.

Official Interaction Statements

  • Use with Probenecid is restricted due to its ability to raise and prolong the plasma concentration of amoxicillin.
  • Co-administration with Methotrexate may result in increased systemic exposure to Methotrexate due to reduced renal clearance.
  • The combination with Oral Anticoagulants (such as Warfarin) is associated with a potential for the prolongation of prothrombin time (INR).
  • Concomitant use with Mycophenolate Mofetil is documented to cause a reduction in the pre-dose concentration of the active metabolite (MPA) of MMF.
  • The official labeling also includes a documented risk of potential reduction in the efficacy of oral contraceptives.

This information is restricted to official regulatory statements defining the product's interaction structure, with specific mention of pharmacokinetic interference and the required timing of administration relative to food intake.

Mechanism of Action

Mechanistic Strategy: Cell Wall Disruption and Defense Neutralization

This section details the compound’s action at the molecular and cellular level, focusing exclusively on its pharmacodynamic mechanisms, targets, and resulting physiological consequences. The strategy relies on two independent but cooperative mechanistic domains: structural disruption and enzymatic defense neutralization.

Irreversible Inhibition of Cell Wall Synthesis

The Amoxicillin component acts by irreversibly inhibiting Penicillin-Binding Proteins (PBPs), the essential bacterial transpeptidase enzymes required for building the structural integrity of the cell wall. This molecular blockade arrests the peptidoglycan cross-linking pathway, initiating a cascade that culminates in the bacterial cell's rupture under osmotic pressure. The resulting physiological effect is the direct induction of bactericidal cell lysis.

Protection of Amoxicillin Against beta-Lactamase

The Clavulanic acid component functions as a suicide inhibitor that chemically disables bacterial beta-Lactamase Enzymes. By irreversibly binding to these enzymes, it strategically protects the Amoxicillin molecule from hydrolytic degradation. This allows the primary bactericidal mechanism to proceed, thereby restoring Amoxicillin's ability to inhibit target enzymes against resistant bacterial strains.

Dosage and Administration Information

Amoxicillin/Clavulanic Acid (AMK) is administered primarily through the oral route using tablets, chewable tablets, or an oral suspension. An intravenous (IV) form is also authorized for administration in clinical settings, typically for initial therapy in severe infections. The official usage protocol mandates that the oral dose must be taken at the start of a meal or with food to minimize potential gastrointestinal intolerance and ensure optimal absorption of the clavulanic acid component.

Standard administration regimens are defined by specific strength ratios and frequencies. Immediate-release tablets are commonly prescribed for administration either three times daily (TID) or twice daily (BID), depending on the formulation and required dose strength. For example, 875 mg/125 mg is typically administered BID. Treatment should generally not exceed a maximum course duration of 14 days without clinical review. The preparation of the oral suspension requires reconstitution with a specified volume of water and subsequent vigorous shaking before each measured dose.

Usage protocols require specific modifications based on patient physiology. Dose adjustment is mandatory for patients diagnosed with impaired renal function, specifically when creatinine clearance (CrCl) is 30 mL/min or lower, which involves reducing the dose frequency to align with official instructions. Pediatric dosing is calculated based on the child's weight. Furthermore, certain special procedural constraints exist, such as the instruction that some tablet score lines are intended only to facilitate swallowing and do not represent a valid division point for administering a half-dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of the research and clinical studies that have investigated this antibacterial substance and its combination with a beta-lactamase inhibitor. It is descriptive of the research scope and does not imply suitability, offer clinical advice, or suggest effectiveness.


Single Substance Studies

Research examined the substance in the context of single-agent studies, which included investigations into its potential application for certain bacterial infections, such as those of the respiratory and urinary tracts.

Efficacy and Safety Scope

Studies focused on objective and subjective measures of infection resolution. Research evaluated the minimum concentration required to inhibit the growth of susceptible bacterial strains. The safety profile was investigated across numerous short-term trials.

  • Adverse Events: Adverse events were recorded, with gastrointestinal disturbance, primarily diarrhea, being among the most common findings in clinical trials involving the single substance.
  • Hypersensitivity: Trial protocols mandated vigilance for serious hypersensitivity reactions, characteristic of the penicillin class of antibiotics.

Combination Therapy Research

Research has also investigated the substance in a fixed-dose combination with a beta-lactamase inhibitor. This inhibitor is included to protect the core antibacterial agent from degradation by bacterial enzymes, which are responsible for resistance.

Observed Effects

Studies confirmed that the combination expands the spectrum of bacteria against which the therapy is investigated. This included resistant strains implicated in conditions such as acute bacterial sinusitis and otitis media. Trial designs incorporated monitoring of liver function markers due to reports of transient hepatic events associated with the combination. The research aims to balance the extended utility of the combination against established safety findings.

Key Studies & References Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury

Frequently Asked Questions (FAQ)

Common questions about AMK (FAQ)


Q: Is it normal to feel a mild side effect when starting AMK?

A: Official documentation from regulatory bodies lists common side effects that may occur, especially when starting the medicine. These frequently reported events include gastrointestinal issues such as diarrhea, nausea, and vomiting, as well as oral or vaginal yeast infections (mucocutaneous candidosis). These findings are based on data collected during clinical trials.

Q: Can AMK affect my ability to drive or operate machinery?

A: Warnings in official documents advise that convulsions (fits) and other neurological effects may occur with this medicine. If these or similar reactions are experienced, ability to drive or operate machinery may be affected. Regulatory warnings indicate that awareness of the medicine’s effects on the individual is important before engaging in such activities.

Q: Is there a generic version of AMK available?

A: Yes, this combination of active ingredients is a well-established medication that is globally recognized and included in the World Health Organization (WHO) Model List of Essential Medicines. As a result, the combination is available in many generic product formulations worldwide, in addition to brand names.

Q: Is AMK classified as a controlled substance?

A: The product is classified as a prescription-only medicine (meaning it requires a prescription from a healthcare professional). However, as a beta-lactam antibiotic, it is not generally scheduled as a controlled substance under regulatory acts like the Controlled Substances Act (CSA) in the United States.

Q: Do I need to change my diet while taking AMK?

A: Official instructions specify that the medicine should be taken at the start of a meal or with food. This specific timing is to help reduce potential stomach upset and aid the absorption of one of the active components. Regulatory documents do not typically specify that other general dietary changes are required during treatment.

Q: Can I drink alcohol moderately while on AMK?

A: Official patient information documents advise that alcohol should generally be avoided during the course of treatment with this medicine. It is also recommended to avoid alcohol for several days following the completion of the course.

Q: How does AMK interact with birth control pills?

A: Official labeling documents note a documented risk that co-administration of this medicine may result in a potential reduction in the efficacy of oral contraceptives. The effect is related to how antibiotics can alter the body’s processes.

Q: Are there any known interactions between AMK and herbal supplements?

A: The safety of taking AMK simultaneously with herbal remedies and supplements has not been tested in clinical trials as extensively as other prescription medicines. Official regulatory documents generally include a statement regarding the importance of sharing information about all medicines, vitamins, and supplements with a healthcare professional.

Q: Why are there different colors/shapes of AMK pills mentioned online?

A: The medicine is manufactured by multiple companies worldwide under various brand and generic names, and in different dosage strengths and forms (e.g., tablets, liquid). Due to this, the pills are expected to have different appearances, including variations in color, shape, and unique imprints.

Q: Can AMK affect sleep patterns?

A: The official adverse reaction data includes reports of central nervous system (CNS) effects, such as dizziness and convulsions (fits). While sleep-specific disorders are not commonly listed as frequent side effects, any CNS effect could indirectly influence sleep patterns. It is important that any unusual changes in sleep are noted.

Q: Is there a risk of dependence or withdrawal with AMK?

A: AMK is a beta-lactam antibiotic used to treat bacterial infections. It is not classified as a controlled substance and is not generally associated with the drug dependence or withdrawal syndromes that are noted with certain other pharmacological classes of drugs.

Q: Does AMK lose effectiveness over time?

A: Regulatory sources and research focus on the risk of antimicrobial resistance, which is when the bacteria themselves evolve to defeat the drug. This is different from the medicine losing inherent effectiveness in the body. Official warnings note that a lack of expected efficacy is a potential adverse event that should be reported.

Q: Is it possible for a side effect of AMK to appear months after starting it?

A: Official safety warnings state that certain serious hepatobiliary events (liver and bile duct issues), such as cholestatic jaundice, may have a delayed onset. These rare events have been documented to appear several weeks, and sometimes months, after treatment has been finished.

Q: What should I do if the medicine doesn't seem to be working?

A: Patient information generally includes guidance to continue the prescribed treatment as instructed. However, if symptoms worsen or do not begin to improve within a few days of starting the medicine, regulatory guidance recommends that a healthcare professional be informed.

Q: Why do some people stop taking AMK?

A: Official warnings state that immediate discontinuation is required if a patient develops signs of a severe allergic reaction (hypersensitivity) or develops antibiotic-associated colitis (severe, persistent diarrhea). These are the main reasons for stopping treatment before the prescribed course is finished.

Q: How soon after stopping AMK is it out of the body?

A: Official pharmacokinetic data indicates that both amoxicillin and clavulanic acid have relatively short half-lives in the body. In patients with normal kidney function, this means that the concentrations of the active substances are typically reduced to very low levels within hours after the last dose.

Q: Does AMK have an impact on mood or mental health?

A: The official adverse reaction profile includes reports of central nervous system (CNS) effects such as dizziness and fits. Specific severe mood or mental health impacts are not consistently listed among the most frequent regulatory side effects, but it is noted that any unusual changes in behavior or mood are important considerations.

Q: Is AMK a new drug, or has it been around for a while?

A: The fixed-dose combination of amoxicillin and clavulanic acid was first introduced in the early 1980s. This gives it a history of over forty years of clinical use, establishing it as a well-known and extensively studied medication.

Q: Can environmental factors affect how AMK works in the body?

A: The way AMK works once inside the body is not generally linked to external environmental factors. However, regulatory-related stability studies indicate that the active ingredients are sensitive to factors like moisture, which is why the dry powder for suspension must be stored carefully before mixing.

Q: What if I take AMK but don't feel any different?

A: Antibiotics work by eliminating the targeted bacteria, which does not always result in an immediate feeling of change. Patient instructions generally include guidance to continue the full treatment course as prescribed and recommend informing a healthcare professional if symptoms do not improve within a few days.

Q: Are there specific times of day AMK should be taken?

A: Official instructions specify that the medicine should be taken at the start of a meal or with food to help minimize the risk of stomach upset. The timing should be consistent with the dose frequency (e.g., twice daily or three times daily) but is not tied to a specific time like morning or evening.

Q: Can AMK be crushed or split?

A: Regulatory guidance often states that standard tablets should be swallowed whole. While some specific tablet score lines may indicate suitability for splitting to ease swallowing, certain critical formulations (like extended-release) are specifically designed not to be crushed or split.

Q: Is AMK safe to use during pregnancy?

A: Official documentation indicates that the use of AMK during pregnancy is conditional and requires caution. It is typically reserved for situations when a healthcare professional clearly establishes a need, and the potential benefit is considered to outweigh any potential risks.

Q: How is AMK different from a vitamin or supplement?

A: AMK is classified as a regulated, prescription-only beta-lactam antibiotic and beta-lactamase inhibitor combination. This classification marks it as a regulated drug used for treating bacterial infections, distinguishing it fundamentally from non-regulated dietary supplements or vitamins.

Q: Can I take AMK if I have a history of heart issues?

A: Regulatory warnings primarily focus on the risk of severe hypersensitivity reactions (anaphylaxis), which can have consequences for the heart. Although there is no general contraindication for common heart issues, it is important that any underlying conditions be communicated to the prescriber for individual assessment.

Q: Are there specific populations for whom AMK is not recommended according to regulatory warnings?

A: Yes, official warnings and contraindications exist for specific populations. These include patients with a known history of penicillin allergy, a prior history of liver problems associated with AMK use, and patients who are suspected of having infectious mononucleosis. Special dosing adjustments are also required for individuals with severe kidney impairment.

How should AMK be stored and disposed of?

Storage and Disposal of Amoxicillin and Clavulanate Potassium

Required Storage Conditions

Amoxicillin and clavulanate potassium tablets and the dry powder for suspension must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The dry product must be kept in its original, tightly closed container and protected from moisture.

Reconstituted Suspension Stability

Once the powder is mixed with water, the liquid suspension must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F) and must not be frozen. The stability period for the refrigerated liquid suspension is 10 days, after which any remaining product must be discarded.

Handling and Disposal

This medication must be kept out of the sight and reach of children. Unused or expired amoxicillin and clavulanate potassium must be disposed of in accordance with local regulatory requirements, often through official medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of AMK found in:

A-Z Index: